At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
NK3R antagonist - AZD4901 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes
In Brief
A Phase 2 clinical trial evaluating NK3R antagonist - AZD4901 and Placebo for Menopausal Flushing. Completed, enrolled 37 participants across 1 site.
Detailed Summary
Placebo-controlled, double-blinded, cross-over clinical trial of a new investigational product
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMenopausal Flushing
CountriesUnited Kingdom
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartFeb 2016
Primary CompletionJan 2017
TodayJul 2026
First PostedJan 29, 2016
Enrollment StartFeb 1, 2016
Primary CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.4 years ago
Interventions
NK3R antagonist - AZD4901drug
Neurokinin 3 receptor antagonist
Placebodrug
Placebo